The investigators aim to compare the efficacy of an IBI targeting complicated grief symptoms (LIVIA 2.0) compared to an already investigated IBI (LIVIA 1) using a guidance on demand design in a randomised controlled trial (RCT). More specifically, the investigators will test the following primary hypotheses: * Both interventions will significantly increase participants' well-being and decrease their distress, and those changes will be stable until follow-up. * LIVIA 2.0 will be more efficient than LIVIA 1 on all measure outcomes. * LIVIA 2.0 will have less dropouts than LIVIA 1.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in complicated grief symptoms
Timeframe: Pretest; 12-week post-test; 3-month Follow-up
Change in depression symptoms
Timeframe: Pretest; 12-week post-test; 3-month Follow-up
Change in well-being
Timeframe: Pretest; 12-week post-test; 3-month Follow-up